Please assess the completion status of the following clinical trial:

Trial Title: COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~* History of chronic heart failure (HF), defined as requiring treatment for HF for a minimum of 4 weeks prior to screening~* Treated with stable, optimal pharmacological therapy for ≥ 4 weeks~* History of left ventricular ejection fraction (LVEF) ≤ 40%~* Elevated N-terminal prohormone B-type natriuretic peptide (NT-proBNP)~Exclusion criteria:~* Severe uncorrected valvular heart disease~* Hospitalization within 30 days prior to enrollment~* Hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, or clinically significant congenital heart disease~* Acute myocardial infarction, unstable angina or persistent angina at rest within 30 days prior to randomization~* Systolic blood pressure \> 160 mmHg or \< 90 mmHg or diastolic blood pressure \> 90 mmHg~* Total bilirubin ≥ 2 x upper limit of normal (ULN); aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 3 x ULN~* Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73m\^2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Dose-escalation Cohort 1: Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo tablets twice a day (BID) for 7 days.
- Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 (Type: EXPERIMENTAL): Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days.
- Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 (Type: EXPERIMENTAL): Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days.
- Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 (Type: EXPERIMENTAL): Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days.
- Dose-escalation Cohort 2: Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo tablets twice a day for 7 days.
- Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 (Type: EXPERIMENTAL): Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days.
- Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 (Type: EXPERIMENTAL): Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days.
- Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 (Type: EXPERIMENTAL): Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days.
- Expansion Phase: Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo tablets twice a day for 20 weeks.
- Expansion Phase: Omecamtiv Mecarbil 25 mg M-F1 (Type: EXPERIMENTAL): Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks.
- Expansion Phase: OM M-F1 PK-based Titration (Type: EXPERIMENTAL): All participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete